Prof Rupert Bauersachs (Clinic Darmstadt, Darmstadt, DE) discusses the results from the VOYAGER PAD trial. The aim of the trial was to evaluate rivaroxaban/aspirin compared with placebo/aspirin among patients with lower extremity peripheral artery disease (PAD) undergoing revascularization.Questions
What is the VOYAGER PAD Trial and what does it aim to address?
What was the study design, patient population and endpoints?
What are the main findings to date?
What conclusions can be made and what are the implications on practice?
What are the next steps?
Recorded remotely from Darmstadt, 2021.
Editor: Mirjam Boros
Музыка
Фильмы
ТВ Шоу
Категории видео
